Lilly releases its most comprehensive corporate responsibility report

Eli LillyEli Lilly and Company (NYSE: LLY) has released its most comprehensive corporate responsibility report using the Global Reporting Initiative (GRI) framework, which is designed to help companies report on economic, environmental and social performance.

"Lilly's greatest contribution to society is continuing to discover and develop innovative medicines that help people live longer, healthier, more active lives," said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer. "To succeed, we must conduct our business ethically, responsibly and transparently - and use our resources, knowledge and capabilities to help improve global health and bring value to patients, society and shareholders."

Lilly, a leader in advocating for greater transparency by the biopharmaceutical industry, provides a comprehensive report of the company's progress on numerous corporate responsibility goals and efforts. The report includes updates on longstanding programs, data for 2010, as well as highlights of initiatives begun in 2011.

Included in the report are highlights indicating that Lilly:

  • helped more than 227,000 people through its patient assistance programs in 2010, a 12 percent increase compared to the previous year;
  • launched a physician payment registry to help people better understand how the company works with doctors to advance research and education;
  • introduced 229 new clinical-trial sites in U.S. locations with diverse populations since 2008;
  • gave approximately $430 million in global charitable contributions in 2010, including cash, products and other in-kind donations;
  • invested its largest-ever education-focused grant ($2.5 million) in a campaign sponsored by The Mind Trust to improve public education for underserved children;
  • launched new five-year, $60 million commitments through The Lilly NCD Partnership and The Lilly MDR-TB Partnership to improve outcomes for underserved populations;
  • received a perfect score of 100 on the Human Rights Campaign's "Best Places to Work: Corporate Equality Index" in 2010;
  • selected 200 employees to volunteer, on company time, in countries where people lack resources or access to quality health care;
  • reduced serious injury and lost-time injury rates each by 33 percent (from 2007 baseline);
  • decreased water intake by more than 30 percent and waste to landfill by 50 percent compared to 2007;
  • improved energy efficiency by more than 12 percent, compared to 2007, and reduced corresponding greenhouse gas emissions by more than 9 percent.

"Our role as a good corporate citizen extends well beyond a desire to be charitable and 'do the right thing' in communities where our employees live and work," Lechleiter said. "Our commitment to corporate responsibility is embedded in our innovation-based business strategy, our culture and the day-to-day operations carried out by Lilly employees worldwide."

The Lilly 2010/11 Corporate Responsibility Report also serves as the company's annual Communication on Progress to the United Nations Global Compact (UNGC). As a signatory of the UNGC, Lilly shares its progress annually on 10 universally accepted principles related to human rights, labor, the environment and anti-corruption.

The report details the company's progress in areas such as:

  • conducting business ethically and transparently, including the safe, uninterrupted supply of medicines, ethical product promotion, patient privacy, public disclosure of clinical trial results and financial payments to health care professionals, and participation in public policy dialogue;
  • enhancing access to medicines and efforts to improve health among underserved populations through The Lilly Global Health Innovation Campaign, patient assistance programs and product donations;
  • developing innovative medicines and maintaining the highest standards in research and development, including the use and care of animals in research, bioethics, patient safety and education, diversity in clinical trials, and the development of tailored medicines that deliver higher value and better outcomes for individual patients;
  • supporting strong workplace practices that encompass diversity and inclusion; employee health, safety and wellness; recruiting, hiring and development; and efforts to help employees maintain work-life balance;
  • engaging with patients and communities to achieve better health outcomes, including community-based programs that support patients with specific diseases, partnerships that focus on improving health disparities, and volunteer and giving programs that mobilize Lilly's global workforce around its vision to improve global health;
  • fostering environmental sustainability and reducing the company's environmental footprint through initiatives related to energy efficiency, greenhouse gas emissions, water intake and waste to landfill.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

Most Popular Now

Amgen and Allergan's MVASI™ (bevacizumab-awwb) and…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a bio...

Compound found in red wine opens door for new trea…

Like to unwind with a glass of red wine after a stressful day? Don't give alcohol all the credit. New research has revealed that the plant compound resveratrol, which is ...

HIV vaccine nears clinical trial following new fin…

A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar p...

Mylan and Upjohn, a division of Pfizer, to combine…

HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's o...

Leading oncologists and nutritionists pinpoint are…

An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship betwe...

Closing the door: breaking new ground related to a…

In order to sustain fast growth, cancer cells need to take up nutrients at a faster rate than healthy cells. The human glutamine transporter ASCT2 allows the amino acid g...

Roche and Spark Therapeutics, Inc. announce extens…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced...

FDA approves first generics of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associat...

FDA approves first treatment for severe hypoglycem…

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that c...

Rye is healthy, thanks to an interplay of microbes

Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribut...

GSK completes transaction with Pfizer to form new …

The Joint Venture brings together two highly complementary portfolios of trusted consumer health brands, including GSK's Sensodyne, Voltaren and Panadol and Pfizer's Advi...

Eating more plant-based foods may be linked to bet…

Eating mostly plant-based foods and fewer animal-based foods may be linked to better heart health and a lower risk of dying from a heart attack, stroke or other cardiovas...